Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Therese S Geraci"'
Autor:
Gabriel B. Habib, Vasilios Papademetriou, David Gordon, Brian Montgomery Sumner, Chuke Nwachuku, Charles E. Ford, Nathan D. Wong, Linda B. Piller, Therese S. Geraci, Puneet Narayan, Thomas J. Hartney, Efrain Reisin, L. Julian Haywood
Publikováno v:
J Clin Hypertens (Greenwich)
The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) consisted of 42,418 participants randomized to one of four antihypertensive treatment groups: chlorthalidone, amlodipine, lisinopril, or doxazosin. A subset of
Autor:
Stephen A Geraci, Therese S. Geraci
Publikováno v:
The Journal of Cardiovascular Nursing. 18:389-395
Hypertension and hyperlipidemia are potent cardiovascular risk factors. Treatment can lower blood pressure and reduce events, but the optimal drug for initial hypertension treatment and the benefits of long-term cholesterol reduction on clinical outc
Autor:
Angela Williard, Sara L. Pressel, Lara M. Simpson, Connie Kingry, Karen L. Margolis, Michael A. Proschan, Juan Alzate, Frans H. H. Leenen, Jeff D. Williamson, Robert Pospisil, John H. Eckfeldt, David C. Goff, I. Kay Dunn, L. Julian Haywood, Suzanne Oparil, Gail T. Louis, Michael H. Alderman, Paul K. Whelton, R. L Sue Ferguson, Anne Juratovac, Brenda Jaeger, David Gordon, Pamela Ragusa, Richard S. Crow, David A. Calhoun, Christine Nelson, Jeanne Russo, William C. Cushman, Therese S. Geraci, Linda B. Piller, Sharon Feldman, Tracy Lucente, Gail Barone, Judy Bettencourt, Kim Jenkins, Peggy McDowell, Lillian Carroll, Jeffrey A. Cutler, Henry R. Black, Jackson T. Wright, Sandra M. Walsh, Joe Blanton, Sheila Sullivan, Rudy Christian, John Pelosi, Richard H. Grimm, Joanna Tanner, Curt D. Furberg, Barbara DeLeon, Janice Johnson, Paula Einhom, Leslie Ann Holland-Klemme, Barry R. Davis, Mahboob Rahman, Jeffrey L. Probstfield, Chuke Nwachuku, Charles E. Ford
Publikováno v:
JAMA: The Journal of the American Medical Association. 288:2981-2997
Autor:
Barbara Kimmel, Sara L. Pressel, Barry R. Davis, Chuke Nwachuku, Charles E. Ford, Christine Lusk, Linda B. Piller, Jackson T. Wright, Judy Bettencourt, Lara M. Simpson, Therese S. Geraci, Curt D. Furberg, Connie Kingry, Heather Parks
Publikováno v:
Controlled Clinical Trials. 22:29-41
The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) is a randomized, practice-based trial sponsored by the National Heart, Lung, and Blood Institute (NHLBI). The double-blind, active-controlled component of ALLHAT
Autor:
Therese S. Geraci, Stephen A. Geraci
Publikováno v:
Southern medical journal. 106(10)
Autor:
Therese S Geraci, Stephen A. Geraci
Publikováno v:
Southern medical journal. 106(7)
Cardiovascular disease is the most common cause of death in women in the United States, and hypertension is a major contributor to cardiovascular mortality. The incidence of hypertension in women is steadily increasing, paralleling the epidemics of o
Autor:
Yves Rosenberg, Laura Vargo, Connie Kingry, Karen L. Margolis, Jeff D. Williamson, Therese S. Geraci, JoAnne M. Sperl-Hillen, Jeffrey L. Probstfield, Brenda Kirpach, Laura C. Lovato, Arnaud Bastien, Gillian L. Booth
Publikováno v:
The American journal of cardiology. 99(12A)
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial is a randomized, multicenter clinical trial using a double 2 × 2 factorial design in 10,251 participants with type 2 diabetes mellitus at high risk for cardiovascular disease (CVD)
Publikováno v:
Clinical nursing research. 7(2)
Although there is extensive information on the disease aspect of heart failure (HF) and chronic obstructive pulmonary disease (COPD), the illness aspect of these diseases has received limited attention. This limitation in our knowledge is of concern
Autor:
Robert J. Capone, Yudi Pawitan, Nabil El-Sherif, Therese S. Geraci, Kathryn Handshaw, Joel Morganroth, Robert C. Schlant, Albert L. Waldo, null The Cast Investigators
Publikováno v:
Journal of the American College of Cardiology. 18(6)
Patients randomized to placebo in the encainide and flecainide arms of the Cardiac Arrhythmia Suppression Trial (CAST) have been found to have a relatively low 1-year mortality rate of 3.9% in comparison with previous studies of patients in the postm